Puma Biotechnology to Present at Cowen's Health Care Conference

This rating was issued on 9/22/16. The stock's price fluctuated within the range of $28.95 - $35.55 during previous trading session.

The stock price of Nasdaq-listed Puma Biotechnology Inc. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Citigroup Inc. reiterated their buy rating on shares of Puma Biotechnology Inc (NYSE:PBYI) in a research report report published on Saturday. On average, analysts predict that Puma Biotechnology will post ($7.87) EPS for the current year. They now have a Dollars 264 price target on the stock. They now have a United States dollars 60 price target on the stock. JP Morgan Maintains Puma Biotechnology, Inc. They now have a Dollars 300 price target on the stock. The firm's current ratio calculated as 1.30 for the most recent quarter Covanta Holding Corporation (CVA) announced that the Board of Directors has declared a quarterly cash dividend of $0.25 per share, payable on April 6, 2017 to stockholders of record as of the close of business on March 30, 2017.

The 6 analysts offering 12-month price forecasts for Puma Biotechnology Inc have a median target of 88.50, with a high estimate of 107.00 and a low estimate of 57.00.

Relative strength index (RSI-14) for Puma Biotechnology Inc (NYSE:PBYI) is at 44.03. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. Currently, the Company is primarily focused on the development of the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell. UBS Asset Management Americas Inc. increased its position in Puma Biotechnology by 2.4% in the third quarter. Tower Research Capital LLC TRC now owns 2,427 shares of the biopharmaceutical company's stock worth $163,000 after buying an additional 1,740 shares in the last quarter. Cowen and Company reissued a market perform rating on shares of Puma Biotechnology in a research note on Tuesday, November 15th. (NASDAQ:PBYI) reported its EPS in the last quarter as $-2.04/Share lagging the analyst estimate of $-1.92/Share by the difference of $-0.12.

The stock is now showing YTD performance of 6.84 Percent. Taking a look into the performance of PBYI stock, investor will come to know that the weekly performance for this stock is valued at -5.48%, resulting in a performance for the month at 1.23%.

Insider Trades for Puma Biotechnology, Inc. show that the latest trade was made on 31 Jan 2017 where Charnas (Robert), the Divisional Officer completed a transaction type "Sell" in which 1000 shares were traded at a price of $31.8.

Puma Biotechnology, Inc. (NASDAQ:PBYI) topped its 52-week high price target of 73.27 on Sep 27, 2016. Stifel Nicolaus reiterated a "buy" rating and issued a $88.00 price target on shares of Puma Biotechnology in a research note on Wednesday, November 30th. Over the last five days, shares have faced -4.66% losses and now is down -20.9% since hitting its 200-day moving average of $3.24.

Puma Biotechnology, Inc. (NASDAQ:PBYI) is now showing its ROA (Return on Assets) of -141.4%. The Monthly and Yearly performances are 1.23 percent and -32.06 percent respectively. (NASDAQ:PBYI) is 11.85. The Average Volume (3 months) is 759.25 Million. It's now trading about -44.58% below its 52-week high. The stock presently has an average rating of "Hold" and an average price target of $68.56.

  • Zachary Reyes